Celebrating 25 years Est 1999-2024
*Across 3 years $3395.52 only $1358.21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Neurotrope Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute...
Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with...
Neurotrope Announces Investor Update Conference Call - Management to Host Investor Conference Call on Thursday, May 28, at 11:00 AM ET - PR...
Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company Lead asset Stendra®...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.